Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulviprubart - Abcuro

Next Previous
Drug Profile

Ulviprubart - Abcuro

Alternative Names: ABC-008; Anti-KLRG1 antibody - Abcuro

Latest Information Update: 19 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abcuro
  • Class Anti-inflammatories; Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; C-type lectin antagonists; Immunologic receptor antagonists; NK cell lectin-like antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Inclusion body myositis
  • Phase I/II Large granular lymphocytic leukaemia
  • Preclinical Autoimmune disorders; Non-Hodgkin's lymphoma

Most Recent Events

  • 12 Feb 2025 Abcuro announces intention to submit BLA for Inclusion body myositis
  • 10 Jan 2025 Abcuro completes a phase I trial for Inclusion body myositis in USA (Parenteral) (NCT04659031)
  • 21 Oct 2024 Abcuro initiates phase II/III clinical trials in Inclusion body myositis (In adults, In the elderly) in USA (SC) (NCT06450886)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top